BioCryst
Manufacturing · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
4505 Emperor Blvd Ste 200, Durham, North...Phone Number
(919) 859-1302Website
www.biocryst.comRevenue
$940.6 MillionStock Symbol
BCRXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About BioCryst
BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals is headquartered in Durham, North Carolina.Explore more
BioCryst Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioCryst your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on BioCryst recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at BioCryst
Product Launch: Get notified when BioCryst launches new products
Check if BioCryst has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if BioCryst had a recent Job posting/layoffs
Check out if BioCryst is spiking on competitors!
BioCryst, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once BioCryst has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to BioCryst
Compare insights from companies similar to BioCryst, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioCryst is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioCryst is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioCryst.
BioCryst financials insights
Gather financial insights about BioCryst, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Grant
$4.1M
Grant
$2.4M
2016
Debt
$23M
2018
Grant
$3.5M
2019
Debt
$100M
Stock Offering
$63M
2021
Other Financing Round
$350M
2023
Debt
$450M
BioCryst Tech Stack
A closer look at the technologies used by BioCryst
See more technologies
Most Recent Scoops
Person-Based
Partnership, Research & Development, Pharmaceuticals
Person-Based
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Research & Development, Corporate Strategy
Left Company
Executive Move
Executive Moves, Left Company
BioCryst News & Media
BioCryst Pharmaceuticals Q2 Earnings Call Highlights
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE. President and CEO Charlie GaBioCryst Reports Second Quarter 2026 Financial Results
— Total net revenue of $218.3 million and ORLADEYO® net revenue of $158.2 million —BioCryst to Report Second Quarter 2026 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026.BioCryst Appoints David W. Jenkins as Chief Scientific Officer
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnership
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioCryst
Sign Up For FreeTo access detailed company insights
BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals is headquartered in Durham, North Carolina.... Read More
